The overall objective of Duke's Clinical Oncology Research Career Development Program (PCACO), now called the Duke Paul Calabresi Award for Clinical Oncology (PCACO) remains the provision of career development support to junior faculty committed to clinical oncology therapeutic research careers at a time when new training methods are required to prepare future academic leaders for the major challenges of oncology research. In the last funding period, we have supported 17 Scholars, 12 male, and 5 female, with 10 Caucasian, 6 Asian, and 1 Hispanic, 14 from Duke and 3 recruited from other institutions including the National Cancer Institute, Johns Hopkins, and St. Jude. Most Scholars were Medical Oncologists (11), but we also supported 3 Surgeons and 1 Gynecologic Oncologist and two PhD scientists focused on pharamcogenetics and biomarkers. At this time, all Scholars are in active clinical and translational positions in academic medicine with 16 of 17 in academic medicine and one in industry. Eleven of 17 Scholars have obtained additional peer reviewed funding or awards including a Burroughs Wellcome Scholar, Doris Duke Clinical Scholar, V Foundation Scholar, Howard Hughes award, 3 K awards, and 3 American Cancer Society Scholars. Scholars have published over 70 peer reviewed manuscripts including reports in high impact journals such as the NEJM, JAMA, Lancet Oncology, Nature, Science, Nature Medicine, Nature Reviews, Journal of Clinical Oncology, Blood, Cancer, Clinical Cancer Research, Cancer Research, and the Journal of Immunology. The proposed PCACO proposes a career development program that allows integration of the enormous breadth of knowledge with the powerful statistical and computational approaches to extract important answers with an understand of the imperatives of managing complex infrastructure, as well as the vital ethical interactions with human experimental subjects

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA100639-09
Application #
8324245
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2003-04-01
Project End
2014-07-31
Budget Start
2012-08-22
Budget End
2013-07-31
Support Year
9
Fiscal Year
2012
Total Cost
$598,126
Indirect Cost
$80,389
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Secord, Angeles Alvarez; Teoh, Deanna; Jia, Jingquan et al. (2014) Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression. Int J Gynecol Cancer 24:218-25
Cheng, Qing; Chang, Jeffrey T; Gwin, William R et al. (2014) A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res 16:407
Mook Jr, Robert A; Chen, Minyong; Lu, Jiuyi et al. (2013) Small molecule modulators of Wnt/*-catenin signaling. Bioorg Med Chem Lett 23:2187-91
Lu, Jiuyi; Chen, Minyong; Ren, Xiu-Rong et al. (2013) Regulation of hedgehog signaling by Myc-interacting zinc finger protein 1, Miz1. PLoS One 8:e63353
Lin, Ningjing; Di, Chunhui; Bortoff, Kathy et al. (2012) Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. Mol Cancer Res 10:208-17
Armstrong, Andrew J; Marengo, Matthew S; Oltean, Sebastian et al. (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9:997-1007
Osada, Takuya; Chen, Minyong; Yang, Xiao Yi et al. (2011) Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 71:4172-82
Osada, T; Hsu, D; Hammond, S et al. (2010) Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 102:124-33
Armstrong, Andrew J; Netto, George J; Rudek, Michelle A et al. (2010) A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 16:3057-66
Lu, Yun; Futtner, Christopher; Rock, Jason R et al. (2010) Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 5:e11022

Showing the most recent 10 out of 16 publications